Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR A1904

Next Previous
X
Search
Drug Profile

SHR A1904

Alternative Names: SHR-A1904

Latest Information Update: 23 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Gastric cancer; Solid tumours
  • Phase I Pancreatic cancer

Most Recent Events

  • 22 Nov 2024 Phase-III clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral), (NCT06649292),
  • 22 Nov 2024 Phase-III clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral), (NCT06649292),
  • 17 Oct 2024 Shanghai Hengrui Pharmaceutical plans a phase III trial for Adenocarcinoma (Metastatic disease, Late-stage disease, Second-line therapy) in China (Parenteral) in November 2024 (NCT06649292)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top